Sesamol attenuates oxidative stress, apoptosis and inflammation in focal cerebral ischemia/reperfusion injury.

The aim of the present study was to evaluate the therapeutic potential of sesamol treatment on focal ischemia/reperfusion (I/R) injury in the rat brain. The results demonstrated that pretreatment with sesamol seven days prior to focal cerebral I/R injury had significant positive effects, including improvements in neurological deficits (P<0.05), and a reduction in malondialdehyde content and elevation of antioxidant levels (superoxide dismutase, glutathione and glutatione peroxidase; both P<0.05). Furthermore, levels of B cell lymphoma-2 (Bcl-2)-associated X protein and caspase-3 were significantly downregulated, whereas the level of Bcl-2 was effectively increased. Conversely, the mRNA expression of proinflammatory cytokines were significantly reduced in focal cerebral I/R injury rats upon sesamol intervention. Therefore, the beneficial effects of sesamol on cerebral I/R injury may be due to the reduction of oxidative stress, inhibition of apoptosis and inflammation. The findings of the present study suggest that sesamol supplementation may serve as potent adjuvant in the treatment of focal cerebral ischemia/reperfusion injury due to its neuroprotective effects.

Expression of survivin in invasive pituitary adenoma.

OBJECTIVE: To investigate the relationship between survivin expression and invasiveness of pituitary adenoma. METHODS: A total of 66 patients, on whom trans sphenoidal surgery had been performed between July 2006 and March 2008, were enrolled in our study at the Department of Neurosurgery in Shandong Provincial Hospital and Jinan Central Hospital, Shandong, P. R. China. All patients were divided into the invasion group (n=39), and the non-invasion group (n=27) by assessment of preoperative MRI and intraoperative inspection. Survivin expression was determined by immunohistochemistry. Statistical analysis of survivin expression between the 2 sample groups was accomplished using the chi-square test. RESULTS: Survivin was expressed in 46 (69.7%) of the investigated pituitary adenomas. For invasive pituitary adenoma, survivin staining was positive in 35 (89.7%), only 11 (40.7%) specimens were positive in noninvasive tumors. The chi-square test demonstrated a statistically significant difference in survivin expression between invasive and noninvasive pituitary adenoma (chi2=14.309, p=0.0002). CONCLUSION: Survivin was highly associated with invasive pituitary adenoma, it is likely to serve as a useful tool for confirmation of invasive pituitary adenoma and the gene could be an effective target for pituitary adenoma gene therapy.

Expression and significance of glucocorticoid receptor alpha in meningiomas.

OBJECTIVE: To explore the expression of the glucocorticoid receptor alpha (GRalpha) and its significance in the occurrence and progress of meningiomas. MATERIALS AND METHODS: By the use of flow cytometry, the proliferative index (PI), S-phase fraction (SPF) and DNA ploidy were detected to evaluate the proliferation of tumor cells in 58 meningioma specimens. The expressions of GRalpha in all meningiomas and seven normal dura samples were studied by means of reverse transcription-polymerase chain reaction to compare the difference in GRalpha between meningiomas and normal dura. The relation between GRalpha and histological grades, PI, SPF and DNA ploidy were also analyzed. RESULTS: The mean PI was 9.32%+/-4.41% while the mean SPF was 2.79%+/-2.43% in 58 meningioma specimens. DNA was diploid in 51 cases and aneuploid in the remaining seven cases, with the aneuploid rate being 12.1%. Nine of 58 meningiomas were GRalpha- negative and the rest were GRalpha-positive with a GRalpha-positive rate of 84.5%. The GRalpha-positive meningiomas included 13 '+', 15 '++', 9 '+++' and 12 '++++'. GRalpha was negative in normal dura samples. The GRalpha-positive rate of meningiomas was significantly greater than that of normal dura. There were no significant differences in PI and SPF among GRalpha-negative, GRalpha-weak positive and GRalpha-strong positive meningiomas. The difference in aneuploid rate between GRalpha-positive and GRalpha-negative meningiomas was also not significant. CONCLUSION: GRalpha is of significance in meningiomas, which are a target tissue for glucocorticoid. However, GRalpha's expression had no obvious effect on the proliferative activity of meningiomas, so it may not be a major control of this process.